Breaking Down SG&A Expenses: Johnson & Johnson vs argenx SE

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, Johnson & Johnson and argenx SE stand as giants, albeit of different scales. Over the past decade, from 2014 to 2023, their Selling, General, and Administrative (SG&A) expenses have painted a vivid picture of their operational strategies. Johnson & Johnson, a stalwart in the industry, consistently reported SG&A expenses averaging around $21 billion annually, with a slight dip in 2022. This reflects their expansive global operations and robust marketing strategies. In contrast, argenx SE, a rising star, has shown a remarkable growth trajectory. Starting with a modest $4 million in 2014, their SG&A expenses surged to $709 million by 2023, highlighting their aggressive expansion and investment in market presence. This comparison not only underscores the scale of operations but also the dynamic nature of the pharmaceutical industry.